Inhibikase Therapeutics Inc
NASDAQ:IKT
Cash Flow Statement
Cash Flow Statement
Inhibikase Therapeutics Inc
Mar-2018 | Sep-2018 | Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow | |||||||||||||||||||||||||
Net Income |
(0)
|
(1)
|
(2)
|
(4)
|
(6)
|
(7)
|
(6)
|
(5)
|
(3)
|
(2)
|
(3)
|
(5)
|
(7)
|
(11)
|
(15)
|
(17)
|
(19)
|
(19)
|
(18)
|
(18)
|
(19)
|
(19)
|
(19)
|
(19)
|
|
Depreciation & Amortization |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Other Non-Cash Items |
0
|
1
|
1
|
2
|
4
|
4
|
4
|
4
|
2
|
1
|
2
|
3
|
3
|
3
|
2
|
2
|
1
|
1
|
1
|
0
|
0
|
0
|
1
|
0
|
|
Cash Interest Paid |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Change in Working Capital |
(0)
|
(0)
|
2
|
2
|
3
|
3
|
2
|
1
|
0
|
1
|
(0)
|
(3)
|
(5)
|
(3)
|
(2)
|
1
|
3
|
0
|
0
|
(2)
|
(1)
|
0
|
0
|
3
|
|
Cash from Operating Activities |
(0)
N/A
|
(0)
-106%
|
1
N/A
|
0
-49%
|
0
-14%
|
1
+116%
|
(0)
N/A
|
(0)
+9%
|
(0)
+16%
|
(0)
+31%
|
(1)
-528%
|
(5)
-325%
|
(9)
-89%
|
(11)
-23%
|
(14)
-28%
|
(14)
N/A
|
(14)
-1%
|
(18)
-24%
|
(17)
+3%
|
(19)
-12%
|
(20)
-1%
|
(18)
+7%
|
(18)
+1%
|
(16)
+12%
|
|
Investing Cash Flow | |||||||||||||||||||||||||
Capital Expenditures |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
0
|
(0)
|
(0)
|
(0)
|
0
|
|
Other Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(21)
|
(16)
|
(22)
|
(19)
|
19
|
12
|
14
|
|
Cash from Investing Activities |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
(0)
N/A
|
(21)
-52 325%
|
(16)
+24%
|
(22)
-36%
|
(19)
+12%
|
19
N/A
|
12
-38%
|
14
+22%
|
|
Financing Cash Flow | |||||||||||||||||||||||||
Net Issuance of Common Stock |
0
|
1
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
15
|
15
|
56
|
56
|
41
|
41
|
0
|
0
|
0
|
9
|
9
|
9
|
9
|
0
|
|
Net Issuance of Debt |
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
|
Other |
0
|
(0)
|
(2)
|
(2)
|
(2)
|
(1)
|
0
|
0
|
(0)
|
(0)
|
0
|
0
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
|
Cash from Financing Activities |
0
N/A
|
1
+708%
|
(0)
N/A
|
(0)
N/A
|
(0)
N/A
|
(1)
-225%
|
(0)
+99%
|
0
N/A
|
0
N/A
|
0
-28%
|
15
+8 267%
|
14
-4%
|
56
+288%
|
56
+0%
|
41
-27%
|
41
+1%
|
(0)
N/A
|
(0)
-18%
|
(0)
N/A
|
9
N/A
|
9
0%
|
9
N/A
|
8
-2%
|
0
-98%
|
|
Change in Cash | |||||||||||||||||||||||||
Net Change in Cash |
(0)
N/A
|
1
N/A
|
0
-45%
|
0
N/A
|
(0)
N/A
|
(1)
-1 260%
|
(0)
+47%
|
(0)
+83%
|
(0)
+83%
|
0
N/A
|
14
+139 300%
|
10
-31%
|
47
+387%
|
45
-4%
|
27
-40%
|
27
+1%
|
(15)
N/A
|
(39)
-167%
|
(34)
+14%
|
(33)
+3%
|
(30)
+7%
|
9
N/A
|
2
-78%
|
(2)
N/A
|
|
Free Cash Flow | |||||||||||||||||||||||||
Free Cash Flow |
(0)
N/A
|
(0)
-106%
|
1
N/A
|
0
-49%
|
0
-14%
|
1
+116%
|
(0)
N/A
|
(0)
+9%
|
(0)
+16%
|
(0)
+31%
|
(1)
-528%
|
(5)
-325%
|
(9)
-89%
|
(11)
-23%
|
(14)
-28%
|
(14)
N/A
|
(14)
-1%
|
(18)
-25%
|
(18)
+3%
|
(19)
-10%
|
(20)
-2%
|
(18)
+8%
|
(18)
+1%
|
(16)
+12%
|